# Clinical Trials Data ALK - Document 20

# Clinical Relevance of ROS (V-ros UR2 Sarcoma Virus Oncogene Homolog) Aberrations in Solid Tumours

## Clinical Trial: https://clinicaltrials.gov/study/NCT01596374

"eligibilityCriteria": "Inclusion Criteria:\n\n- Patients with cancer",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "21 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Department of Pathology, NUH Tissue Repository, The samples collected for the study are leftover clinical samples and the patients have consented for their samples to be used for research.",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided information, a patient with an ALK gene mutation would be eligible for the clinical trial, as the inclusion criteria specify "Patients with cancer." The presence of an ALK gene mutation typically indicates a type of cancer, which would meet the basic inclusion requirement.   
  
There doesn't seem to be any exclusion criteria noted here that would disqualify such a patient specifically for having an ALK gene mutation. However, it would be important for the patient to also meet other unspecified inclusion criteria, consent criteria, and logistical requirements related to sample availability and previous consent for research use of their samples.